Literature DB >> 16036044

Vasopressin antagonists in heart failure.

Ladan Golestaneh1, Ashok Talreja, Thierry H Le Jemtel.   

Abstract

The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16036044     DOI： 10.1007/s11897-004-0008-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  30 in total

Review 1.  Vasopressin: a therapeutic target in congestive heart failure?

Authors:  S R Goldsmith
Journal:  J Card Fail       Date:  1999-12       Impact factor: 5.712

Review 2.  Loop diuretics: from the Na-K-2Cl transporter to clinical use.

Authors:  Sudha S Shankar; D Craig Brater
Journal:  Am J Physiol Renal Physiol       Date:  2003-01

3.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Authors:  Alexander L Gerbes; Veit Gülberg; Pere Ginès; Guy Decaux; Peter Gross; Hassan Gandjini; Jacques Djian
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

4.  Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells.

Authors:  Udo Hasler; David Mordasini; Marcelle Bens; Matthieu Bianchi; Francoise Cluzeaud; Martine Rousselot; Alain Vandewalle; Eric Feraille; Pierre-Yves Martin
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

Review 5.  Physiology and pathophysiology of renal aquaporins.

Authors:  S Nielsen; T H Kwon; B M Christensen; D Promeneur; J Frøkiaer; D Marples
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

Review 6.  Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure.

Authors:  Stuart D Russell; Tracy DeWald
Journal:  Am J Cardiovasc Drugs       Date:  2003       Impact factor: 3.571

7.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

Authors:  Michael Domanski; James Norman; Bertram Pitt; Mark Haigney; Stephen Hanlon; Eliot Peyster
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

8.  Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.

Authors:  M Naitoh; H Suzuki; M Murakami; A Matsumoto; K Arakawa; A Ichihara; H Nakamoto; K Oka; Y Yamamura; T Saruta
Journal:  Am J Physiol       Date:  1994-12

9.  A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.

Authors:  Florence Wong; Andres T Blei; Laurence M Blendis; Paul J Thuluvath
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

10.  Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.

Authors:  Mareo Naitoh; John Risvanis; Leanne C Balding; Colin I Johnston; Louise M Burrell
Journal:  Cardiovasc Res       Date:  2002-04       Impact factor: 10.787
View more
  1 in total

1.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.